Drug Trial Radar · NCT04914351
HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours
Last checked: Nov 19, 2026Latest source record: Mar 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
17
Actual
Start
May 3, 2022
Primary completion
Nov 27, 2023
Study completion Dec 30, 2023
Sponsor
- Lead sponsor
- Shanghai HyaMab Biotech Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 4, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I, first-in-human trial to evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of HY-0102 administered intravenously (IV) once every two weeks in adult patients with locally advanced/metastatic malignant solid tumors.
Conditions
- Locally Advanced/Metastatic Solid Tumors
Interventions
HY-0102Drug
Multiple dose cohorts, 60 minute IV infusion, every two weeks, 28 days as a cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of Drug Limited Toxicities (DLTs)Time frame: From Time of First dose through DLT observation period, 28 days
- Incidence of Treatment-emergent adverse event (TEAEs) and serious adverse events (SAEs).Time frame: From the start of treatment until up to 90 days after the last dose of study drug
- Number of patients with changes in laboratory parameters from baselineTime frame: From the start of treatment until up to 30(±7) days after the last dose of study drug
- Number of patients with changes in electrocariogram (ECG) from baselineTime frame: From the start of treatment until up to 30(±7) days after the last dose of study drug
- Number of participants with changes in left ventricular ejection fraction (LVEF) from baselineTime frame: From the start of treatment until up to 30(±7) days after the last dose of study drug
- Number of participants with changes in Clinically Significant Vital Sign from baselineTime frame: From the start of treatment until up to 30(±7) days after the last dose of study drug
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Sarah Cannon Research Institute
Orlando, Florida
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Texas Oncology
Tyler, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.